Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM27FAN)

• Drug Name: JNJ-78278343 Drug Info
• Synonyms: JNJ-8343

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM27FAN

Molecule-Related Drug Atlas

Drug(s) Targeting Tissue kallikrein (KLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avoralstat	DM5YHU2	Hereditary angioedema	4A00.14	Phase 2/3	[2]
VDA-1102	DMAJ85O	Actinic keratosis	EK90.0	Phase 2	[3]
JNJ-69086420	DM6VR13	Prostate cancer	2C82.0	Phase 1	[4]
JNJ-75229414	DMV6XBC	Prostate cancer	2C82.0	Phase 1	[5]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[6]
DM-107	DMRYQVJ	Atopic dermatitis	EA80	Investigative	[7]
hK2p01 derivative KLK2 inhibitor	DME13RQ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[10]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[11]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[12]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[13]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[14]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[15]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[16]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[17]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]
Tissue kallikrein (KLK2)	TTJLNAW	KLK2_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Vidac Pharma.
• [4] ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [6] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
• [8] Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.
• [9] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [10] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [11] Clinical pipeline report, company report or official report of Genmab.
• [12] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [13] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [14] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [15] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [16] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [17] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [18] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.